FibroBiologics, Inc.(FBLG)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
FBLG Stock Analysis & AI Quality Score
AI stock analysis and institutional research for FibroBiologics, Inc. (FBLG), a Healthcare sector company. FBLG is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), FibroBiologics, Inc. reports net income of $-5.0M, free cash flow of $-4.4M. Top institutional holders of FBLG by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Fund Evaluation Group,, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. FBLG trades on the Nasdaq exchange and files with the SEC under CIK 1958777. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FBLG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for FibroBiologics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-5.0M
Free Cash Flow
Q1 2026
$-4.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-13.1% YoYOperating Income
-87.3% YoYEPS (Diluted)
+38.2% YoYTotal Assets
-18.6% YoYTotal Debt
Op. Cash Flow
-156.1% YoY| Metric | FY 2025 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Net Income | $-18.6M -13.1% | $-16.5M -221.9% | $-5.1M | — |
| Operating Income | $-16.6M -87.3% | $-8.9M -99.0% | $-4.5M | — |
| EPS (Diluted) | $-0.42 +38.2% | $-0.68 -277.8% | $-0.18 | — |
| Total Assets | $9.6M -18.6% | $11.8M +145.0% | $4.8M | — |
| Total Debt | — | — | $60.0K | — |
| Operating Cash Flow | $-16.4M -156.1% | $-6.4M -57.4% | $-4.1M | — |
AI Insight: FBLG Financial Trends
FibroBiologics shows persistent operating losses with erratic equity swings, burning cash across eight consecutive quarters without revenue disclosure.
• Operating losses remained consistently high, ranging from $-3M to $-5M across all quarters since Q2 2024.
• Operating cash flow improved from $-5M in Q1 2025 to $-3M in Q4 2025 before deteriorating to $-4M in Q1 2026.
• Equity swung dramatically from $0M in Q3 2025 to $6M in Q4 2025, then dropped to $3M in Q1 2026.
⚠ No revenue reported across eight quarters suggests pre-commercial stage with ongoing cash burn risk.
⚠ Equity volatility indicates potential dilutive financing events that could impact shareholder value.
AI Insight: FBLG Ratio Trends
Data is too sparse to identify meaningful financial trends for FibroBiologics across the available periods.
• ROA deteriorated sharply from 40.3% in Q2 2024 to -75.4% in Q4 2024.
⚠ Most financial ratios lack data across recent quarters, limiting visibility into operational performance.
Get alerted when FBLG's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for FibroBiologics, Inc. including:
Top Institutional Holders of FBLG
VANGUARD CAPITAL MANAGEMENT LLC
$89.3K67,665 shFund Evaluation Group, LLC
$68.4K51,794 shGEODE CAPITAL MANAGEMENT, LLC
$39.1K29,609 shBlackRock, Inc.
$32.5K24,647 shCascade Financial Partners, LLC
$21.7K16,428 shRENAISSANCE TECHNOLOGIES LLC
$21.1K15,997 shVANGUARD FIDUCIARY TRUST CO
$8.4K6,380 shUBS Group AG
$7.6K5,721 shVanguard Global Advisers, LLC
$708.00536 shTower Research Capital LLC (TRC)
$607.00460 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $89.3K | 67,665 |
| Fund Evaluation Group, LLC | $68.4K | 51,794 |
| GEODE CAPITAL MANAGEMENT, LLC | $39.1K | 29,609 |
| BlackRock, Inc. | $32.5K | 24,647 |
| Cascade Financial Partners, LLC | $21.7K | 16,428 |
| RENAISSANCE TECHNOLOGIES LLC | $21.1K | 15,997 |
| VANGUARD FIDUCIARY TRUST CO | $8.4K | 6,380 |
| UBS Group AG | $7.6K | 5,721 |
| Vanguard Global Advisers, LLC | $708.00 | 536 |
| Tower Research Capital LLC (TRC) | $607.00 | 460 |
More Healthcare Companies
View all Healthcare →Put FBLG on your watchlist
Track score changes the day FibroBiologics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is FBLG a good stock to buy?
13F Pro's AI-powered analysis of FibroBiologics, Inc. (FBLG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FBLG are available on the FBLG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own FBLG?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FBLG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of FibroBiologics, Inc.'s investment landscape.